drugset / Trial / NCT05296772
Phase 1 First-in-human Study of JS014
NaSequentialOpen-labelTreatment
Summary
This phase 1, first-in-human study uses a BOIN design to assess the safety and potential efficacy of JS014 at different dose levels as a single agent and in combination with fixed dose of pembrolizumab in subjects with advanced cancer.
Timeline
- Start
- 2022-02-28
- Primary completion
- 2024-06
- Completion
- 2025-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JS014 | Protein / enzyme biologic | — | — |
| Background | Pembrolizumab | Monoclonal antibody | 200 mg | — |